

BRAIN Biotech AG

Creating a #BiobasedFuture

G-dase E[®] Pharma Licensing Agreement with Akribion Therapeutics GmbH

Adriaan Moelker, CEO

Michael Schneiders, CFO

Zwingenberg, November 5th, 2024

WE SUPPORT



Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment and anti-corruption.



Safe Harbor Statement

This document may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties, as they relate to future events and are based on current assumptions of the Company, which may not occur at all in the future or may not occur as assumed. They do not represent a guarantee for future results or performance of the Company, and the development of economic and legal conditions may materially differ from the information expressed or implied in the forward-looking statements.

The Company assumes no obligation to update or revise any forward-looking statement contained herein or to adapt them to future events or developments. The information contained in this document has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinion contained herein. The Company or any of its shareholders, affiliates, advisors, employees or representatives shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its content or otherwise arising in connection with this document.

By accepting this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business.

This presentation speaks as of October 31st, 2024. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The term "BRAIN", as used in this presentation means BRAIN Biotech AG and its affiliates, if not otherwise specified.

Exclusive Pharma Licensing Agreement for G-dase E[®] CRISPR-Cas Technology

our next major value creation from BRAIN's BioIncubator pipeline

- **Another Milestone Transaction:** long-term value creation from our **BioIncubator pipeline**
- **Agreement enables high upside capture** from pharma development
- BRAIN Biotech will Participate on G-dase E[®] pharma upside for a **very long period**
- VC is the **better owner:** increasing probability of success, add industry expertise and source of funding
- **Focusing BRAIN Biotech further** on the core BioProducts business
- **Accelerating our path to profitability** with significant immediate cost savings, starting from Q2 24/25
- Realizing our commitment to **monetize the BioIncubator**

Deal Structure – Commercial Terms

immediate costs savings while maintaining significant upside potential for our shareholders

- **BRAIN and Akribion Therapeutics GmbH sign an exclusive license agreement for G-dase E[®] development and commercialization for pharmaceutical applications**
- **BRAIN Biotech receives up to EUR 92.3 million in R&D and commercial milestones**
 - Based on clinical development progress and market success
- **Royalties in addition**
 - Based on net sales
- **Secured an extended time frame for the harvesting period**
 - Essential given long lead times in pharma

Deal Structure -- Operations

immediate costs savings while maintaining significant upside potential for our shareholders

➤ Akribion Therapeutics GmbH (ATx)

- Lead by Co-CEOs Lukas Linnig and Dr. Michael Krohn
- Joined by a pharma-oriented developer and scientific team of BRAIN Biotech employees
- Commencement of operation: December 1st 2024
- Backed by an experienced VC consortium with a focus on early-stage pharma development, seed extension
- Sufficient initial financing to reach inflection point
- First focus: in-vivo technology enabling and studies
- BRAIN will keep providing services and space for ATx at arm's length (SLA)

Deal Structure -- Operations

patent portfolio stays with BRAIN Biotech

- **Exclusive license to ATx for pharma development as announced**
- **All non-licensed fields will be further developed and commercialized by BRAIN Biotech**
 - Target projects include Strain development/yield improvement for enzymes and other target molecules e.g. in the alternative proteins market
 - “We CRISPR for You” an additional TMS service
 - Possibility to license to other third parties

CMD 2024 – December 12th in Zwingenberg

with an additional live stream

- **We are looking forward to welcoming you in Zwingenberg & Online**
- **One additional topic covered:** further insights into the CRISPR-Cas technology current-use and development plans within BRAIN Biotech

Thank you very much for your interest.



BRAIN Biotech AG

Darmstädter Straße 34–36
64673 Zwingenberg, Germany

+49 (0) 6251-9331-0
www.brain-biotech-group.com

Your contacts:

Adriaan Moelker, CEO

Michael Schneiders, CFO

Martina Schuster, IR
+49 (0) 6251-9331-69
IR@brain-biotech.com

 [brainbiotechag](https://twitter.com/brainbiotechag)

 [BRAIN Biotech AG](https://www.linkedin.com/company/brain-biotech-ag)

 [BRAIN Biotech AG](https://www.youtube.com/channel/UC...)

 [@BRAINbiotech](https://twitter.com/@BRAINbiotech)